Evidence map›Paper›PMID 34941963›Full record

ArticlePLoS pathogens2021

Evolution of protection after maternal immunization for respiratory syncytial virus in cotton rats.

Jorge C G Blanco, Lori M Cullen, Arash Kamali, Fatoumata Y D Sylla, Marina S Boukhvalova, Trudy G Morrison

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jorge C G BlancoSigmovir Biosystems, Inc., Rockville, Maryland, United States of America.
Lori M CullenUniversity of Massachusetts Chan Medical School, Worcester, Massachusetts United States of America.ORCID 0000-0001-6696-9875
Arash KamaliSigmovir Biosystems, Inc., Rockville, Maryland, United States of America.
Fatoumata Y D SyllaSigmovir Biosystems, Inc., Rockville, Maryland, United States of America.
Marina S BoukhvalovaSigmovir Biosystems, Inc., Rockville, Maryland, United States of America.
Trudy G MorrisonUniversity of Massachusetts Chan Medical School, Worcester, Massachusetts United States of America.ORCID 0000-0003-2800-7717
Sigmovir Biosystems (United States) · USUniversity of Massachusetts Chan Medical School · US

Funding

Development of an RSV vaccine for the elderlyR01AI143896 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MORRISON, TRUDY G. · 2020 to 2024
$3.6M
Development of VLP vaccine for RSVR44AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2019 to 2021
$3.5M
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung InjuryR01AI125215 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLANCO, JORGE C, VOGEL, STEFANIE N. · 2017 to 2021
$2.7M
Development of VLP vaccine for RSVR42AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2016 to 2017
$1.9M
Development of VPL Vaccine for RSVR41AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2014 to 2014
$225k
NIAID NIH HHS R01 AI143896NIAID NIH HHS R41 AI109926NIAID NIH HHS R42 AI109926NIAID NIH HHS R44 AI109926
6 · The paper itself

Abstract

Maternal anti-respiratory syncytial virus (RSV) antibodies acquired by the fetus through the placenta protect neonates from RSV disease through the first weeks of life. In the cotton rat model of RSV infections, we previously reported that immunization of dams during pregnancy with virus-like particles assembled with mutation stabilized pre-fusion F protein as well as the wild type G protein resulted in robust protection of their offspring from RSV challenge. Here we describe the durability of those protective responses in dams, the durability of protection in offspring, and the transfer of that protection to offspring of two consecutive pregnancies without a second boost immunization. We report that four weeks after birth, offspring of the first pregnancy were significantly protected from RSV replication in both lungs and nasal tissues after RSV challenge, but protection was reduced in pups at 6 weeks after birth. However, the overall protection of offspring of the second pregnancy was considerably reduced, even at four weeks of age. This drop in protection occurred even though the levels of total anti-pre-F IgG and neutralizing antibody titers in dams remained at similar, high levels before and after the second pregnancy. The results are consistent with an evolution of antibody properties in dams to populations less efficiently transferred to offspring or the less efficient transfer of antibodies in elderly dams.

Indexed as

Antibodies, ViralRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAnimalsAntibodies, NeutralizingFemaleImmunizationLungNosePregnancySigmodontinaeAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus Vaccines

Identifiers

PMID34941963
PMCPMC8741018
OpenAlexW4200256610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.